xcellbio
Improving therapeutic performance for predictive clinical outcomes through in vitro microenvironment control.
San Francisco, United States
29 employees
Corporate Round
Total: $39.60M
Biotechnology, Health Care +2
General Information
Get notified when xcellbio moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track xcellbio
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biotechnology
About xcellbio
Taxonomy: Life Science, Cell Therapy, Primary Cell Culture, Immunotherapy, Stem Cells, Cancer Research, Predictive Clinical Outcomes, Immunooncology, In Vitro Microenvironment Control, Cell Manufacturing, Immune Cells, Therapeutic Performance, Startup, San Francisco, Disruptive Technology
Funding Rounds & Investors (5)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Corporate Round | •••••• | 1 |
|
01 Apr 2024 |
| Series B | •••••• | 5 |
|
19 Jan 2022 |
| Series A | •••••• | 1 |
|
16 Feb 2017 |
| Venture Round | •••••• | 1 |
|
06 May 2015 |
| Convertible Note | •••••• | 1 | •••• •••• | 01 Oct 2014 |
xcellbio Alternatives & Competitors
Introducing new cell engineering options to the world through culture media
The one-stop shop for human and animal primary cells, customized media, and cell culture tools.
Enhance your research with antibody-free human primary cells and optimized media. An AnaBios Company...
vs
Celularity Inc.
FAQ About xcellbio
Don't just browse. Track.
Signal Tracker monitors xcellbio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
